Protease Inhibitors

"Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).

Descriptor ID	D011480
MeSH Number(s)	D27.505.519.389.745
Concept/Terms	Protease Inhibitors Protease Inhibitors Inhibitors, Protease Endopeptidase Inhibitors Inhibitors, Endopeptidase Protease Inhibitor Inhibitor, Protease Peptide Hydrolase Inhibitors Hydrolase Inhibitors, Peptide Inhibitors, Peptide Hydrolase Peptide Peptidohydrolase Inhibitors Inhibitors, Peptide Peptidohydrolase Peptidohydrolase Inhibitors, Peptide Protease Antagonists Antagonists, Protease Antiproteases Peptidase Inhibitors Inhibitors, Peptidase

Below are MeSH descriptors whose meaning is more general than "Protease Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]

Below are MeSH descriptors whose meaning is related to "Protease Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Protease Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Protease Inhibitors" by people in this website by year, and whether "Protease Inhibitors" was a major or minor topic of these publications.

Bar chart showing 51 publications over 23 distinct years, with a maximum of 6 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	2	2
1997	1	0	1
1998	2	1	3
1999	0	1	1
2000	0	1	1
2001	0	1	1
2002	0	1	1
2003	0	2	2
2004	1	1	2
2005	0	2	2
2006	1	2	3
2007	1	4	5
2008	4	2	6
2009	3	2	5
2010	2	1	3
2011	2	1	3
2012	1	0	1
2013	1	1	2
2017	3	0	3
2018	0	1	1
2020	1	0	1
2021	1	0	1
2023	0	1	1

Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.

Tobin NH, Murphy A, Li F, Brummel SS, Fowler MG, Mcintyre JA, Currier JS, Chipato T, Flynn PM, Gadama LA, Saidi F, Nakabiito C, Koos BJ, Aldrovandi GM. Metabolomic profiling of preterm birth in pregnant women living with HIV. Metabolomics. 2023 10 25; 19(11):91.

View in: PubMed
Al-Wahaibi LH, Mostafa A, Mostafa YA, Abou-Ghadir OF, Abdelazeem AH, Gouda AM, Kutkat O, Abo Shama NM, Shehata M, Gomaa HAM, Abdelrahman MH, Mohamed FAM, Gu X, Ali MA, Trembleau L, Youssif BGM. Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. Bioorg Chem. 2021 11; 116:105363.

View in: PubMed
Mahmoudzadeh R, Heidari-Keshel S, Mehrpour M, Asadi Amoli F, Aghajanpour L, Lashay A. Comparison of Topical Pigment Epithelium-Derived Factor (PEDF) with Topical Bevacizumab for Accelerating the Regression of Corneal Neovascularization in an Experimental Model of Rabbit Corneal Angiogenesis. Ocul Immunol Inflamm. 2021 Nov 17; 29(7-8):1471-1477.

View in: PubMed
Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):209-213.

View in: PubMed
Cohen JD, Cziraky MJ, Jacobson TA, Maki KC, Karalis DG. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. J Clin Lipidol. 2017 Jul - Aug; 11(4):891-900.

View in: PubMed
Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-na?ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017 04; 140:151-157.

View in: PubMed
Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. 2017; 22(5):413-420.

View in: PubMed
Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother. 2014; 58(2):647-53.

View in: PubMed
Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Res. 2013 Sep; 99(3):214-20.

View in: PubMed
Lawitz EJ, Hill JM, Marbury T, Demicco MP, Delaney W, Yang J, Moorehead L, Mathias A, Mo H, McHutchison JG, Rodriguez-Torres M, Gordon SC. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients. Antivir Ther. 2013; 18(3):311-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement